Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with Candida spp.
ARDS
Acute respiratory disease syndrome
COVID-19
Dysbiosis
Mycobiome
NGS
Next-generation sequencing
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
06
11
2021
revised:
03
02
2022
accepted:
06
02
2022
pubmed:
13
2
2022
medline:
31
3
2022
entrez:
12
2
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic has intensified interest in how the infection affects the lung microbiome of critically ill patients and how it contributes to acute respiratory distress syndrome (ARDS). We aimed to characterize the lower respiratory tract mycobiome of critically ill patients with COVID-19 in comparison to patients without COVID-19. We performed an internal transcribed spacer 2 (ITS2) profiling with the Illumina MiSeq platform on 26 respiratory specimens from patients with COVID-19 as well as from 26 patients with non-COVID-19 pneumonia. Patients with COVID-19 were more likely to be colonized with Candida spp. ARDS was associated with lung dysbiosis characterized by a shift to Candida species colonization and a decrease of fungal diversity. We also observed higher bacterial phylogenetic distance among taxa in colonized patients with COVID-19. In patients with COVID-19 not colonized with Candida spp., ITS2 amplicon sequencing revealed an increase of Ascomycota unassigned spp. and 1 Aspergillus spp.-positive specimen. In addition, we found that corticosteroid therapy was frequently associated with positive Galactomannan cell wall component of Aspergillus spp. among patients with COVID-19. Our study underpins that ARDS in patients with COVID-19 is associated with lung dysbiosis and that an increased density of Ascomycota unassigned spp. is present in patients not colonized with Candida spp.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 pandemic has intensified interest in how the infection affects the lung microbiome of critically ill patients and how it contributes to acute respiratory distress syndrome (ARDS). We aimed to characterize the lower respiratory tract mycobiome of critically ill patients with COVID-19 in comparison to patients without COVID-19.
METHODS
METHODS
We performed an internal transcribed spacer 2 (ITS2) profiling with the Illumina MiSeq platform on 26 respiratory specimens from patients with COVID-19 as well as from 26 patients with non-COVID-19 pneumonia.
RESULTS
RESULTS
Patients with COVID-19 were more likely to be colonized with Candida spp. ARDS was associated with lung dysbiosis characterized by a shift to Candida species colonization and a decrease of fungal diversity. We also observed higher bacterial phylogenetic distance among taxa in colonized patients with COVID-19. In patients with COVID-19 not colonized with Candida spp., ITS2 amplicon sequencing revealed an increase of Ascomycota unassigned spp. and 1 Aspergillus spp.-positive specimen. In addition, we found that corticosteroid therapy was frequently associated with positive Galactomannan cell wall component of Aspergillus spp. among patients with COVID-19.
CONCLUSION
CONCLUSIONS
Our study underpins that ARDS in patients with COVID-19 is associated with lung dysbiosis and that an increased density of Ascomycota unassigned spp. is present in patients not colonized with Candida spp.
Identifiants
pubmed: 35150910
pii: S1201-9712(22)00088-1
doi: 10.1016/j.ijid.2022.02.011
pmc: PMC8828296
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-240Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614
pubmed: 32719848
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Biomed Res Int. 2021 Feb 23;2021:6670798
pubmed: 33681368
N Engl J Med. 2015 Oct 8;373(15):1445-56
pubmed: 26444731
J Hosp Infect. 2001 Mar;47(3):239-42
pubmed: 11247686
Pathogens. 2019 May 21;8(2):
pubmed: 31117285
Antonie Van Leeuwenhoek. 2019 Oct;112(10):1409-1423
pubmed: 31079344
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33087440
Intensive Care Med. 2021 Mar;47(3):292-306
pubmed: 33559707
Microorganisms. 2021 Jan 16;9(1):
pubmed: 33467079
Am J Physiol Lung Cell Mol Physiol. 2015 Nov 15;309(10):L1047-55
pubmed: 26432870
Clin Infect Dis. 2022 Jan 7;74(1):83-91
pubmed: 33693551
BMJ Open. 2020 Jul 12;10(7):e036452
pubmed: 32660950
Clin Microbiol Infect. 2019 Oct;25(10):1200-1212
pubmed: 31039444
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
Sci Rep. 2021 May 12;11(1):10103
pubmed: 33980943
Microbiome. 2018 Dec 17;6(1):226
pubmed: 30558668
Infection. 2021 Aug;49(4):591-605
pubmed: 33709380
Curr Opin Microbiol. 2021 Aug;62:21-27
pubmed: 34034082
Microorganisms. 2021 Feb 26;9(3):
pubmed: 33652802
J Fungi (Basel). 2020 Sep 06;6(3):
pubmed: 32899996
PLoS Pathog. 2015 Jul 09;11(7):e1004923
pubmed: 26158874
EBioMedicine. 2020 Oct;60:102995
pubmed: 32950001
Mycoses. 2021 Feb;64(2):132-143
pubmed: 33210776
J Fungi (Basel). 2020 Oct 08;6(4):
pubmed: 33050019
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Methods Mol Biol. 2018;1849:113-129
pubmed: 30298251
J Fungi (Basel). 2020 Nov 11;6(4):
pubmed: 33187364
J Clin Microbiol. 2011 May;49(5):1866-71
pubmed: 21411591
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Nat Rev Immunol. 2017 Oct;17(10):635-646
pubmed: 28604735
Aging (Albany NY). 2021 Mar 19;13(6):7745-7757
pubmed: 33744863
Intensive Care Med. 2020 Nov;46(11):2071-2074
pubmed: 32902729
Clin Microbiol Infect. 2016 Jan;22(1):94.e1-94.e8
pubmed: 26369603
PLoS One. 2016 May 20;11(5):e0155033
pubmed: 27206014